Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (NYSE:LLY)

Analysis of Revenues

Advanced level

Revenues as Reported

Eli Lilly & Co., Income Statement, Revenues

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016
Diabetes 11,834,400  11,132,100  11,702,100  10,085,200  8,082,800 
Oncology 5,319,300  4,614,400  4,260,500  3,811,900  3,721,800 
Immunology 2,461,900  1,793,300  1,140,000  605,100  113,100 
Neuroscience 1,831,300  1,722,900  1,820,700  2,171,000  2,720,300 
Cardiovascular —  —  2,254,300  2,871,100  3,225,400 
Other human pharmaceutical products 3,092,800  3,056,800  235,600  241,400  200,500 
Human pharmaceutical products 24,539,700  22,319,500  21,413,200  19,785,700  18,063,900 
Animal health products —  —  3,142,500  3,085,600  3,158,200 
Revenue 24,539,700  22,319,500  24,555,700  22,871,300  21,222,100 

Based on: 10-K (filing date: 2021-02-17), 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21).

Item Description The company
Revenue Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Eli Lilly & Co.’s revenue decreased from 2018 to 2019 but then increased from 2019 to 2020 not reaching 2018 level.